SALBUTAMOL HFA METERED-DOSE AEROSOL

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

SALBUTAMOL (SALBUTAMOL SULFATE)

Pieejams no:

SANIS HEALTH INC

ATĶ kods:

R03AC02

SNN (starptautisko nepatentēto nosaukumu):

SALBUTAMOL

Deva:

100MCG

Zāļu forma:

METERED-DOSE AEROSOL

Kompozīcija:

SALBUTAMOL (SALBUTAMOL SULFATE) 100MCG

Ievadīšanas:

INHALATION

Vienības iepakojumā:

200 DOSES

Receptes veids:

Prescription

Ārstniecības joma:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Produktu pārskats:

Active ingredient group (AIG) number: 0108887003; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2014-02-10

Produkta apraksts

_ _
_ _
_ _
_Page 1 of 24_
PRODUCT MONOGRAPH
PR
SALBUTAMOL HFA
salbutamol sulfate inhalation aerosol
(100 mcg salbutamol/metered dose)
Bronchodilator
(beta
2
-adrenergic agonist)
SANIS HEALTH INC.
1 Presidents Choice Circle
Brampton, Ontario
L6Y 5S5
Date of Revision:
July 3, 2018
Submission Control No.: 216774
_ _
_ _
_ _
_ _
_Page 2 of 24_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................3
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND STABILITY
..........................................................................................14
SPECIAL HANDLING INSTRUCTIONS
.......................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
PART II: SCIENTIFIC INFORMATION
...............................................................................15
PHARMACEUTICAL INFORMATION
..........................................................................15
CLINICAL TRIALS
...................................